MET + Vildagliptin Group

Hospital de Clinicas de Porto Alegre · FDA-approved active Small molecule

MET + Vildagliptin Group is a Combination antidiabetic agent (biguanide + DPP-4 inhibitor) Small molecule drug developed by Hospital de Clinicas de Porto Alegre. It is currently FDA-approved for Type 2 diabetes mellitus. Also known as: Galvus®, Glyburide, Glucophage.

This combination uses metformin to reduce hepatic glucose production and improve insulin sensitivity, while vildagliptin inhibits DPP-4 to increase incretin-mediated insulin secretion and reduce glucagon.

This combination therapy uses metformin to reduce hepatic glucose production and improve insulin sensitivity, while vildagliptin inhibits DPP-4 to increase incretin-mediated insulin secretion and reduce glucagon. Used for Type 2 diabetes mellitus.

At a glance

Generic name	MET + Vildagliptin Group
Also known as	Galvus®, Glyburide, Glucophage
Sponsor	Hospital de Clinicas de Porto Alegre
Drug class	Combination antidiabetic agent (biguanide + DPP-4 inhibitor)
Target	Metformin: mitochondrial glycerophosphate dehydrogenase; Vildagliptin: DPP-4 (dipeptidyl peptidase-4)
Modality	Small molecule
Therapeutic area	Diabetes
Phase	FDA-approved

Mechanism of action

Metformin is a biguanide that decreases hepatic gluconeogenesis and improves peripheral insulin sensitivity. Vildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that prolongs the action of incretin hormones (GLP-1 and GIP), thereby enhancing glucose-dependent insulin secretion and suppressing glucagon secretion. Together, they provide complementary mechanisms for glycemic control in type 2 diabetes.

Approved indications

• Type 2 diabetes mellitus

Common side effects

• Gastrointestinal disturbance (nausea, diarrhea, abdominal discomfort)
• Hypoglycemia
• Headache
• Nasopharyngitis

Key clinical trials

• Effects of Vildagliptin Versus Glibenclamide on Glycemia After Exercise in Patients With Type 2 Diabetes (PHASE4)
• Galvus on Met Phase 4 Study : Study to Evaluate the Efficacy and Safety of Early Combination of Vildagliptin and Metformin in Patients With Type 2 Diabetes Mellitus (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• MET + Vildagliptin Group CI brief — competitive landscape report
• MET + Vildagliptin Group updates RSS · CI watch RSS
• Hospital de Clinicas de Porto Alegre portfolio CI

Frequently asked questions about MET + Vildagliptin Group

What is MET + Vildagliptin Group?

MET + Vildagliptin Group is a Combination antidiabetic agent (biguanide + DPP-4 inhibitor) drug developed by Hospital de Clinicas de Porto Alegre, indicated for Type 2 diabetes mellitus.

How does MET + Vildagliptin Group work?

This combination uses metformin to reduce hepatic glucose production and improve insulin sensitivity, while vildagliptin inhibits DPP-4 to increase incretin-mediated insulin secretion and reduce glucagon.

What is MET + Vildagliptin Group used for?

MET + Vildagliptin Group is indicated for Type 2 diabetes mellitus.

Who makes MET + Vildagliptin Group?

MET + Vildagliptin Group is developed and marketed by Hospital de Clinicas de Porto Alegre (see full Hospital de Clinicas de Porto Alegre pipeline at /company/hospital-de-clinicas-de-porto-alegre).

Is MET + Vildagliptin Group also known as anything else?

MET + Vildagliptin Group is also known as Galvus®, Glyburide, Glucophage.

What drug class is MET + Vildagliptin Group in?

MET + Vildagliptin Group belongs to the Combination antidiabetic agent (biguanide + DPP-4 inhibitor) class. See all Combination antidiabetic agent (biguanide + DPP-4 inhibitor) drugs at /class/combination-antidiabetic-agent-biguanide-dpp-4-inhibitor.

What development phase is MET + Vildagliptin Group in?

MET + Vildagliptin Group is FDA-approved (marketed).

What are the side effects of MET + Vildagliptin Group?

Common side effects of MET + Vildagliptin Group include Gastrointestinal disturbance (nausea, diarrhea, abdominal discomfort), Hypoglycemia, Headache, Nasopharyngitis.

What does MET + Vildagliptin Group target?

MET + Vildagliptin Group targets Metformin: mitochondrial glycerophosphate dehydrogenase; Vildagliptin: DPP-4 (dipeptidyl peptidase-4) and is a Combination antidiabetic agent (biguanide + DPP-4 inhibitor).

Related

• Drug class: All Combination antidiabetic agent (biguanide + DPP-4 inhibitor) drugs
• Target: All drugs targeting Metformin: mitochondrial glycerophosphate dehydrogenase; Vildagliptin: DPP-4 (dipeptidyl peptidase-4)
• Manufacturer: Hospital de Clinicas de Porto Alegre — full pipeline
• Therapeutic area: All drugs in Diabetes
• Indication: Drugs for Type 2 diabetes mellitus
• Also known as: Galvus®, Glyburide, Glucophage